12:00 AM
 | 
Aug 15, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Afrezza: Phase III start

MannKind said FDA confirmed the protocols of 2 Phase III trials of Afrezza requested by FDA in a January complete response letter. The open-label, international Phase III Study 171 trial will compare Afrezza using the inhaler MannKind used in Phase III testing vs. Afrezza administered via the MedTone commercial inhaler or injected rapid-acting insulin in Type I diabetics. The placebo-controlled, international...

Read the full 281 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >